AM21-42: Creating a Meaningful Self-Assessment Program for Your Transfusion Service
Oct 19, 2021 1:30pm ‐ Oct 19, 2021 2:30pm
Expiration Date: Dec 31, 2023
Credits: None available.
How much is not enough? How much is too much? Creating a comprehensive and meaningful internal assessment program can seem like a daunting project, especially if you are trying to do it alone! This session will focus on practical quality audits that any transfusion service can develop, schedule, and perform that meet accreditation requirements for self-assessment, add value to your quality program by uncovering problem areas to focus on, and promote ongoing quality improvement. Examples of various internal audits and easy-to-follow audit tools will be shared, as well as tips on how to grow and maintain your self-assessment program by utilizing your own team members as assessors with the goal of maximizing the benefits to be gained from a robust internal quality audit program. You can do this!!! We're here to help you.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Review accreditation requirements for an internal assessment program.
- Identify various internal audits that best measure performance.
- Utilize strategies for creating audit tools that are easy to use and encourage the development of your staff’s quality detective skills.
- Discuss helpful tips on how to strengthen and maintain your internal assessment program.
Speaker(s):
- Ms. Suzanne H. Butch, MLS(ASCP)SBB, Consultant, Michigan Medicine
Speaker(s):
- Sheri Goertzen, MLS(ASCP)BB, CLS(CA), CQA(ASQ), Valley Children’s Hospital and Healthcare
Disclosures
- Suzanne Butch, MLS(ASCP)SBB:
Nothing to Disclose
AM21-43: Histocompatibility Cases in Hematopoietic Stem Cell Transplantation (HSCT): HLA and Beyond
Oct 19, 2021 1:30pm ‐ Oct 19, 2021 2:30pm
Expiration Date: Dec 31, 2023
Credits: None available.
Histocompatibility in HSCT is more than just identifying a 10/10 HLA-matched donor. Have you ever wondered about how HLA-DPB1 (DP) is different to other HLA loci and why we use different terms like “permissive” and “nonpermissive mismatches”? Ever wanted a (very) basic introduction to killer cell immunoglobulin-like receptor (KIR) and how some places use KIR typing in donor selection? And how about the different types of donor chimerism and their clinical significance when it is not a straightforward 100% chimerism result?
In this session, we will bring a case-based approach in highlighting key teaching points on some of these aspects of histocompatibility. Don’t worry if you do not have prior knowledge; we will provide the introductions. This session is categorized as “Intermediate” only because we going beyond the basics of HLA.
This session is an extension of and inspired by feedback from last year’s session “A Step Above the Basics of HLA for Apheresis/Transfusion Practitioners”.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Perform an HLA-DPB1 (DP) mismatch assessment.
- Explain what KIR is and how "B haplotype" gene content is assessed and can be applied in donor selection.
- Describe the aspects behind a donor chimerism report and how they correlate to various clinical scenarios.
- Utilize online tools, databases, websites, and other online resources commonly utilized by HLA experts.
Speaker(s):
- Harold Sullivan, MD, Co-Director of HLA Laboratory; Director of Cellular Therapy Laboratory, Emory University School of Medicine
- Dr. Deanna C. Fang, MD, UC San Diego School of Medicine
Disclosures
- Harold Sullivan, MD:
Nothing to Disclose
- Deanna Fang, MD:
Nothing to Disclose
AM21-44: Assessment and Treatment of COVID-19 Coagulopathy
Oct 19, 2021 2:45pm ‐ Oct 19, 2021 3:45pm
Expiration Date: Dec 31, 2023
Credits: None available.
This program will describe what is currently known about the unique thrombo-inflammatory coagulopathic response associated with SARS-CoV2 infection, how it is uniquely different from other thrombotic disorders, and how current testing strategies including the use of thromboelastography/rotational thromboelastometry can be used to assess or to understand COVID-19 associated coagulopathy. Finally. anticoagulant strategies to prevent and treat COVID-19 associated coagulopathy will be evaluated, along with discussion of the latest clinical treatment trial results.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Describe the thrombo-inflammatory response associated with COVID-19 coagulopathy and how it is different from other thrombotic disorders
- Describe testing approaches to assess COVID-19 coagulopathy
- Describe the latest anticoagulant strategies for the prevention and treatment of COVID-19 coagulopathy
Moderator(s):
- Edward . Wong, MD, Medical Director, Coagulation, Quest Diagnostics
Speaker(s):
- Dr. Cyril Jacquot, MD, PhD, Children's National Hospital
- Dr. Adam Cuker, MD, MS, Hospital of the University of Pennsylvania
Disclosures
- Cyril Jacquot, MD, PhD:
Nothing to Disclose
- Adam Cuker, MD, MS:
Consultant: Synergy; Royalties: UpToDate; Grant/Research Support: Alexion, Bayer, Novartis, Novo Nordisk, Pfizer, Sanofi, Spark, Takeda
- Edward Wong, MD:
Stock Shareholder, Full-time/Part-time Employee: Quest Diagnostics
AM21-45: New Developments in Optimizing Transfusion Management for Major Bleeding: "One Size Does Not Fit All Causes"
Oct 19, 2021 3:45pm ‐ Oct 19, 2021 4:45pm
Expiration Date: Dec 31, 2023
Credits: None available.
This proposed session will explore recent developments in our understanding of the effect of transfusion interventions and diagnostic tests in major bleeding. A common massive hemorrhage protocol cannot be recommended for all causes of major bleeding, and interventions need to be tailored by cause of bleeding. For example, patients with major bleeding due to gastrointestinal need a different management approach to those with obstetric bleeding or trauma (red cell transfusions, tranexamic acid). Many centers that treat massively bleeding patients rely on viscoelastic hemostatic assays to provide information about the coagulation status of their patients. Recently a large randomized trial of injured patients found that bleeding and survival was not different between patients resuscitated with either a viscoelastic or conventional coagulation strategy. This talk will review this and other studies on diagnostic tests and discuss our current standards for monitoring major bleeding.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Interpret the evidence for different interventions and blood components that are available for resuscitating massively bleeding patients (trauma, gastrointestinal, obstetric) and what transfusion thresholds are indicated for these patients
- Appraise results from the latest clinical trials evaluating viscoelastic or conventional coagulation testing strategies for monitoring resuscitation in massively bleeding patients
- Translate the outputs of the session into practical changes to local policies of guidelines for the support of patients with major bleeding
Moderator(s):
- Dr. Monica B. Pagano, MD, Division Head of Transfusion Medicine, Medical Director Transfusion Services, University of Washington
Speaker(s):
- Simon Stanworth, FRCP FRCPath DPhil, Professor of Haematology and Transfusion Medicine; Consultant Haematologist, University Oxford
- Mark Yazer, MD, University Pittsburgh
Disclosures
- Simon Stanworth, FRCP FRCPath DPhil:
Nothing to Disclose
- Monica Pagano, MD:
Nothing to Disclose
- Mark Yazer, MD:
Consultant, Honoraria: Grifols, Macopharma, Octapharma, Terumo, Haemonetics, Cook Biotech, Verax Biomed, New Health Sciences, Aktivax, Cerus
AM21-46: Oral Abstract Session -- Transfusion Medicine and Cellular Therapy Innovation
Oct 19, 2021 2:45pm ‐ Oct 19, 2021 3:45pm
Expiration Date: Dec 31, 2023
Credits: None available.
Oral abstract session focused on Transfusion Medicine and Cellular Therapy Innovation.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- List demographic factors that impact anti-COVID-19 antibody levels in convalescent plasma donors.
- Describe the qualities of antibody responses in blood donors who either had a prior COVID-19 infection or were vaccinated against COVID-19.
- List proteomic markers that improve engraftment potential of fetal liver-derived hematopoietic stem cells.
- Discuss steps that can be taken to improve survival of biotinylated red blood cells.
Moderator(s):
- Thomas Gniadek, MD, PHD, University of Chicago (NorthShore) Pathology
- Dr. Mary Berg, MD, Professor of Clinical Practice, Pathology Medical Director, Transfusion Services, University of Colorado
Speaker(s):
- Dr. Bryan R. Spencer, PhD, American Red Cross Scientific Affairs
- Kim Vanuytsel, Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center
- Amy Schmidt, MD, PhD, CSL
- Tamir Kanias, PhD, Vitalant Research Institute; University of Colorado
Disclosures
- Kim Vanuytsel:
Consultant: CSL Plasma
- Amy Schmidt, MD, PhD:
Consultant: CSL Plasma
- Thomas Gniadek, MD, PHD:
Consultant: Fresenius Kabi
AM21-47: Red Blood Cell Transfusion of Preterm Infants in the 21st Century: High Level Evidence to Guide Practice
Oct 19, 2021 5:00pm ‐ Oct 19, 2021 6:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
In 2020, three large Phase III Randomized Control Trials (RCTs) that focused on neonatal red blood cell transfusions were published. Two studies evaluated the long term neurocognitive and mortality outcomes of pre-term infants receiving red blood transfusions at high and low hemoglobin thresholds. The third study assessed the use of erythrocyte stimulating agent (erythropoietin) to improve neuroprotection of extremely low birth weight infants (birth weight ≤ 1000 grams). The results of these RCTs will help shape the future of red blood cell transfusion in this highly vulnerable population. This joint AABB/ISBT session will not only discuss the results of these transformative studies but will also explore limitations of these type of trials and the future of optimizing RBC transfusion for these patients.
Franz AR, et al. JAMA. 2020;324(6):560-570. Juul SE, et al. N Engl J Med. 2020;382(3):233-243. Juul SE, et al. Jama, Pediatr. 2020;174(10):933-943.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Describe optimal pre-transfusion haemoglobin thresholds for preterm infants.
- Evaluate the benefits and risks of high dose erythropoietin for premature neonates.
- Formulate research priorities to optimize neonatal red blood cell transfusion strategies.
Moderator(s):
- Helen New, NHS Blood and Transplant
Speaker(s):
- Cassandra D. Josephson, MD, Johns Hopkins School of Medicine and Johns Hopkins All Children’s Hospital
- Lani Lieberman, MD, University Health Network
Disclosures
- Cassandra Josephson, MD:
Grant/Research Support: Medtronics, Octapharma LLC; Consultant: Cellphire, Immuncor, LLC, Medtronics
- Helen New:
Nothing to Disclose
- Lani Lieberman, MD:
Nothing to Disclose
AM21-48: Oral Abstract Session -- Innovation in Apheresis and other Therapeutic Approaches
Oct 19, 2021 5:00pm ‐ Oct 19, 2021 6:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
Oral abstract session focused on Innovation in Apheresis and other Therapeutic Approaches.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Moderator(s):
- Dr. Jay S. Raval, MD, Associate Professor, Vice Chair, Director, University of New Mexico
- Grace Lee, MD, Assistant Professor, Duke University Medical Center
Speaker(s):
- John Markantonis, DO, Department of Pathology, University of Texas Southwestern Medical Center
- Jenna Wade, MD, Emory University School of Medicine
- Hollie Reeves, DO, University Hospitals Cleveland Medical Center, Department of Pathology
- Xiaowu Wu, MD, US Army Institute of Surgical Research
Disclosures
- John Markantonis, DO:
Nothing to Disclose
- Jay Raval, MD:
Consultant: Sanofi Genzyme/Terumo BCT
- Grace Lee, MD:
Nothing to Disclose
AM21-49: Tips and Tools to Overcome Challenges and Negotiate Partnerships for Biotherapy Trials
Oct 19, 2021 5:00pm ‐ Oct 19, 2021 6:00pm
Expiration Date: Dec 31, 2023
Credits: None available.
This program encompasses the experiences from two institutions after facing challenging opportunities of becoming partners with sponsors or manufacturers and principal investigators in order to provide support for a particular study or research project.
The presenters will share institutional and personal experiences in the recent past and will provide smart and practical solutions to overcome issues and challenges for those institutions whom are requested to participate and being able to support cutting edge science and its applications in the clinical setting.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Utilize practical tools to start a partnership with a sponsor.
- Relate from similar experiences on how to negotiate critical aspects of the trial.
- Manage resources (human and material) in order to be successful.
- Create their own checklist to include all minimum elements before initiation of a trial.
Moderator(s):
- Dr. Jennifer L. Chain, PhD, Science Officer for Cellular Therapies, Oklahoma Blood Institute
Speaker(s):
- Ronit Slotky, PhD, MSc, Director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center
- Federico Rodriguez Quezada, SBB, MLS(ASCP), Collections and Processing Lab Facility Manager, UFHealth Shands
Disclosures
- Ronit Slotky, PhD, MSc:
Nothing to Disclose
- Jennifer Chain, PhD:
Nothing to Disclose
- Federico Rodriguez Quezada, SBB, MLS(ASCP):
Nothing to Disclose
AM21-50: Oral Abstract Session -- Transfusion Medicine Adverse Events (Pediatric and Adult)
Oct 19, 2021 6:15pm ‐ Oct 19, 2021 7:15pm
Expiration Date: Dec 31, 2023
Credits: None available.
Oral abstract session focused on transfusion medicine adverse events in pediatric and adult settings.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Moderator(s):
- Dr. Mark K. Fung, MD, PhD, Director of Clinical Laboratories, University of Vermont Medical Center
- Robert DeSimone, MD, Director of Transfusion Medicine, Weill Cornell Medicine
Speaker(s):
- Andres Mindiola Romero, MD, Dh
- Ravi Patel, MD, MSC, Emory University School of Medicine
- Eric . Gehrie, MD, MS, Executive Physician Director, Therapeutic & Cellular Solutions, American Red Cross
- Dr. Jay S. Raval, MD, Associate Professor, Vice Chair, Director, University of New Mexico
Disclosures
- Jay Raval, MD:
Consultant: Sanofi Genzyme/Terumo BCT
- Mark Fung, MD, PhD:
Consultant: Cerus Corporation, Biocogniv; Honoraria: Grifols Corporation
- Robert DeSimone, MD:
Consultant: Sanofi Genzyme/Terumo BCT
AM21-51: Telapheresis (Telemedicine in Apheresis) in the Era of the Sars-Cov-2 Pandemic: Will This Become a New Normal?
Oct 19, 2021 6:15pm ‐ Oct 19, 2021 7:15pm
Expiration Date: Dec 31, 2023
Credits: None available.
The SARS-CoV-2 pandemic has helped to create new opportunities for telehealth practices in apheresis medicine. This session will offer an overview of telemedicine in apheresis ("telapheresis"), including descriptions of single-center, mobile, and telapheresis models, the benefits and risks of telapheresis, virtual expert apheresis consultation, telapheresis physician privileging, and HIPAA (Health Insurance Portability and Accountability Act) compliant electronic communication. Discussion of telapheresis medical-legal and ethical concerns, and guidance regarding coding and reimbursement strategies will be addressed. The session will briefly review physician peer-to-peer virtual consultation, virtual apheresis order templates, video telephony platforms, how to handle apheresis complications via telapheresis, and operational and logistical considerations regarding implementation of telapheresis programs. The American Society For Apheresis (ASFA) and the American Association of Blood Banks (AABB) should continue to take the lead in this emerging field and develop standards & guidelines for "best practices" in telapheresis.
To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Learning Objectives:
- Define the essentials of telemedicine in apheresis ("telapheresis"), compare three therapeutic apheresis (TA) delivery models, summarize the pros and cons of telapheresis, and provide guidance on where telapheresis can (and should not) be utilized.
- Describe pre-pandemic Blood Centers' experiences with telehealth practices, and operational considerations regarding implementation of telapheresis programs.
- Evaluate the appropriate utilization of physician-to-physician virtual consultation, and coding and reimbursement strategies for telapheresis consultation and remote TA procedure supervision.
Moderator(s):
- Dr. Chester Andrzejewski, Jr., PhD, MD, FCAP, Medical Director of System Transfuion Medicine, Baystate Health
Speaker(s):
- Walter Linz, MD, MBA, Mayo Clinic
- Dr. Jan C. Hofmann, MD, MPH, UCSF School of Medicine
Disclosures
- Chester Andrzejewski, Jr., PhD, MD, FCAP:
Nothing to Disclose
- Walter Linz, MD, MBA:
Nothing to Disclose
- Jan Hofmann, MD, MPH:
Consultant: Fresenius Medical Care